Phio Pharmaceuticals Corp expected to post a loss of 36 cents a share - Earnings Preview
08/08/2025 15:14
Phio Pharmaceuticals Corp PHIO.OQ PHIO.O is expected to report resultson August 12 (estimated) for the period ending June 30 2025 LSEG's mean analyst estimate for Phio Pharmaceuticals Corp is for a loss of 36 cents per share. The one available analyst rating on the shares is "buy". The average consensus recommendation for the biotechnology & medical research peer group is also "Buy". Wall Street's median 12-month price target for Phio Pharmaceuticals Corp is $14.00, about 83.9% above its last closing price of $2.25 This summary was machine generated August 8 at 14:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing